Results 71 to 80 of about 2,193 (158)

CRISPR Screening and Comparative LC‐MS Analysis Identify Genes Mediating Efficacy of Delamanid and Pretomanid against Mycobacterium tuberculosis

Advanced Science
Tuberculosis (TB), the leading cause of death from bacterial infections worldwide, results from infection with Mycobacterium tuberculosis (Mtb). The antitubercular agents delamanid (DLM) and pretomanid (PMD) are nitroimidazole prodrugs that require ...
Mei‐Yi Yan, Haifeng Li, Yun‐Mo Qu, Si‐Shang Li, Dandan Zheng, Xiao‐Peng Guo, Zhaojun Wu, Jie Lu, Yu Pang, Weimin Li, Jian Yang, Lingjun Zhan, Yi‐Cheng Sun   +12 more
doaj   +1 more source

Efficacy and safety data on pretomanid for drug-resistant TB

IJTLD Open
SUMMARY OBJECTIVE To summarise the efficacy and safety of pretomanid (Pa) based regimens in patients with drug-resistant TB (DR-TB). METHODS We included clinical trials, operational research and observational studies ...
H.T.T. Thuy, C. Padmapriyadarsini, C. Chuchottaworn, S. Foraida, S. Hadigal, A.R. Birajdar   +5 more
openaire   +3 more sources

Recent advancements in tuberculosis (TB) treatment regimens

Journal of Family Medicine and Primary Care
Tuberculosis (TB) remains a global health challenge, with an estimated 10.6 million new cases and 1.3 million deaths in 2022. Recent years have seen a 3.9% increase in TB incidence, reversing prior declines.
Shyamala Ravikoti, Vikas Bhatia, Saykkulandai Kuppuswamy Mohanasundari   +2 more
doaj   +1 more source

Global child-friendly anti-TB medicines – where do we stand?

IJTLD Open
SUMMARY: An increasing number of children are diagnosed and started on antituberculosis treatment. Despite progress in developing child-friendly antituberculosis formulations for drug-susceptible and drug-resistant TB, a single-medicine rifampicin ...
H.S. Schaaf, D.T. Wademan, L.E. van der Laan   +2 more
doaj   +1 more source

Hepatic Safety of Bedaquiline, Delamanid, and Pretomanid: A Systematic Review and Meta-analysis

International Journal of Mycobacteriology
Novel anti-tuberculosis (TB) drugs have been shown to effectively treat drug-resistant TB (DR-TB). However, there is a risk of hepatotoxicity. We aimed to evaluate the incidence of hepatotoxicity in TB patients receiving bedaquiline (BDQ), delamanid (DLM)
Mohamad Faisal Said Al Omar, Izz Eddin Majed Alchikhsuliman, Sondos Mahmoud Awad, Numa Rajab, Yousef Mohammed Alawi, Leena Yousif Mohamed Ibrahim, Idris Sula, Muhammad Candragupta Jihwaprani, Nazmus Saquib   +8 more
doaj   +1 more source

Pharmacology of emerging drugs for the treatment of multi-drug resistant tuberculosis

Journal of Clinical Tuberculosis and Other Mycobacterial Diseases
Mycobacterium tuberculosis (TB) remains the leading cause of infection-related mortality worldwide. Drug resistance, need for multiple antimycobacterial agents, prolonged treatment courses, and medication-related side effects are complicating factors to ...
Tanner M. Johnson, Christina G. Rivera, Grace Lee, John D. Zeuli   +3 more
doaj   +1 more source

Antimycobacterial Drugs as a Novel Strategy to Inhibit Pseudomonas aeruginosa Virulence Factors and Combat Antibiotic Resistance: A Molecular Simulation Study

Microbiology Research
Antimicrobial resistance poses a severe threat, particularly in developing countries where the ready availability of drugs and increased consumption lead to improper antibiotic usage, thereby causing a surge in resistance levels compared to developed ...
Razique Anwer
doaj   +1 more source

Dynamic PET reveals compartmentalized brain and lung tissue antibiotic exposures of tuberculosis drugs

Nature Communications
Tuberculosis (TB) remains a leading cause of death, but antibiotic treatments for tuberculous meningitis, the deadliest form of TB, are based on those developed for pulmonary TB and not optimized for brain penetration.
Xueyi Chen, Bhavatharini Arun, Oscar J. Nino-Meza, Mona O. Sarhan, Medha Singh, Byeonghoon Jeon, Kishor Mane, Maunank Shah, Elizabeth W. Tucker, Laurence S. Carroll, Joel S. Freundlich, Charles A. Peloquin, Vijay D. Ivaturi, Sanjay K. Jain   +13 more
doaj   +1 more source

A Concise Biocatalytic Synthesis of Pretomanid

, 2022
Yuxuan Ye, Todd Hyster
openaire   +1 more source

Dose optimization of TBI-223 for enhanced therapeutic benefit compared to linezolid in antituberculosis regimen

Nature Communications
TBI-223, a novel oxazolidinone for tuberculosis, is designed to provide improved efficacy and safety compared to linezolid in combination with bedaquiline and pretomanid (BPaL).
Natasha Strydom, Jacqueline P. Ernest, Marjorie Imperial, Belén P. Solans, Qianwen Wang, Rokeya Tasneen, Sandeep Tyagi, Heena Soni, Andrew Garcia, Kristina Bigelow, Martin Gengenbacher, Matthew Zimmerman, Min Xie, Jansy P. Sarathy, Tian J. Yang, Véronique Dartois, Eric L. Nuermberger, Radojka M. Savic   +17 more
doaj   +1 more source